US 11,655,477 B2
Methods for thaxtomin production and engineered non-native Streptomyces with increased thaxtomin production
Rosemary Loria, Gainesville, FL (US); Yucheng Zhang, Gainesville, FL (US); Yousong Ding, Gainesville, FL (US); and Guangde Jiang, Gainesville, FL (US)
Assigned to University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Appl. No. 16/616,059
Filed by University of Florida Research Foundation, Inc., Gainesville, FL (US)
PCT Filed May 23, 2018, PCT No. PCT/US2018/034071
§ 371(c)(1), (2) Date Nov. 22, 2019,
PCT Pub. No. WO2018/217855, PCT Pub. Date Nov. 29, 2018.
Claims priority of provisional application 62/509,792, filed on May 23, 2017.
Claims priority of provisional application 62/646,626, filed on Mar. 22, 2018.
Prior Publication US 2020/0140905 A1, May 7, 2020
Int. Cl. C12N 15/76 (2006.01); C12N 1/20 (2006.01); C12P 17/16 (2006.01); A01N 63/28 (2020.01)
CPC C12N 15/76 (2013.01) [A01N 63/28 (2020.01); C12N 1/20 (2013.01); C12P 17/165 (2013.01); C12N 2510/02 (2013.01)] 19 Claims
 
1. A genetically engineered Streptomyces bacterium comprising:
a Streptomyces bacterium from a non-pathogenic Streptomyces strain, the Streptomyces bacterium comprising an exogenous, non-native thaxtomin biosynthetic gene cluster from a pathogenic Streptomyces strain, such that the exogenous non-native thaxtomin biosynthetic cluster provides the genetically engineered Streptomyces bacterium with the ability to produce thaxtomin compounds, thaxtomin intermediates, or combinations thereof, wherein the non-pathogenic Streptomyces strain without the exogenous non-native thaxtomin biosynthetic cluster does not have the ability to produce thaxtomin compounds, thaxtomin intermediates, or combinations thereof, and wherein the genetically engineered Streptomyces bacterium produces about the same or a greater amount of thaxtomin compounds, thaxtomin intermediates, or combinations thereof than S. scabiei under the same culture conditions.